RU2472525C2 - Универсальная вакцина для лечения и профилактики болезни лайма для применения у людей и в ветеринарии и способ ее производства - Google Patents
Универсальная вакцина для лечения и профилактики болезни лайма для применения у людей и в ветеринарии и способ ее производства Download PDFInfo
- Publication number
- RU2472525C2 RU2472525C2 RU2010123897/15A RU2010123897A RU2472525C2 RU 2472525 C2 RU2472525 C2 RU 2472525C2 RU 2010123897/15 A RU2010123897/15 A RU 2010123897/15A RU 2010123897 A RU2010123897 A RU 2010123897A RU 2472525 C2 RU2472525 C2 RU 2472525C2
- Authority
- RU
- Russia
- Prior art keywords
- borrelia
- vaccine
- ospa
- ospc
- universal
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 77
- 208000016604 Lyme disease Diseases 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title description 7
- 241000589969 Borreliella burgdorferi Species 0.000 claims abstract description 46
- 108700023315 OspC Proteins 0.000 claims abstract description 31
- 230000001681 protective effect Effects 0.000 claims abstract description 27
- 241001148604 Borreliella afzelii Species 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000002163 immunogen Effects 0.000 claims abstract description 13
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 230000001580 bacterial effect Effects 0.000 claims abstract description 10
- 108700006640 OspA Proteins 0.000 claims abstract description 8
- 239000012528 membrane Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 229960001212 bacterial vaccine Drugs 0.000 claims abstract description 5
- 239000006166 lysate Substances 0.000 claims abstract description 4
- 241000589968 Borrelia Species 0.000 claims description 43
- 239000000427 antigen Substances 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000000568 immunological adjuvant Substances 0.000 claims description 5
- 101710116435 Outer membrane protein Proteins 0.000 claims description 4
- 239000007975 buffered saline Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 241001148605 Borreliella garinii Species 0.000 abstract description 23
- 230000036039 immunity Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 208000035056 Tick-Borne disease Diseases 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 2
- 230000002354 daily effect Effects 0.000 description 54
- 208000015181 infectious disease Diseases 0.000 description 42
- 101710105714 Outer surface protein A Proteins 0.000 description 35
- 238000002255 vaccination Methods 0.000 description 20
- 241000282472 Canis lupus familiaris Species 0.000 description 16
- 241000282326 Felis catus Species 0.000 description 14
- 241000282412 Homo Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000011888 autopsy Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 241000238876 Acari Species 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 241000283086 Equidae Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000012770 revaccination Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241000699800 Cricetinae Species 0.000 description 6
- 241000283073 Equus caballus Species 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000007390 skin biopsy Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010241 blood sampling Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001480843 Ixodes ricinus Species 0.000 description 4
- 241000589970 Spirochaetales Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229940042470 lyme disease vaccine Drugs 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 108010033266 Lipoprotein(a) Proteins 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 239000010985 leather Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229940099789 ospa protein Drugs 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241000908522 Borreliella Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 238000013494 PH determination Methods 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000035145 Arthropod-borne disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101001086191 Borrelia burgdorferi Outer surface protein A Proteins 0.000 description 1
- 101900341263 Borrelia burgdorferi Outer surface protein A Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101710105715 Outer surface protein B Proteins 0.000 description 1
- 101710105711 Outer surface protein C Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 208000007865 relapsing fever Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 208000016523 tick-borne infectious disease Diseases 0.000 description 1
- 201000006427 tick-borne relapsing fever Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZPV2007-791 | 2007-11-14 | ||
| CZ20070791A CZ301244B6 (cs) | 2007-11-14 | 2007-11-14 | Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby |
| PCT/CZ2008/000130 WO2009062454A2 (en) | 2007-11-14 | 2008-10-21 | Universal vaccine for the treatment and prophylaxis of lyme disease for human and veterinary use and method of its manufacture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010123897A RU2010123897A (ru) | 2011-12-20 |
| RU2472525C2 true RU2472525C2 (ru) | 2013-01-20 |
Family
ID=40600158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010123897/15A RU2472525C2 (ru) | 2007-11-14 | 2008-10-21 | Универсальная вакцина для лечения и профилактики болезни лайма для применения у людей и в ветеринарии и способ ее производства |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2219670A2 (cs) |
| CZ (1) | CZ301244B6 (cs) |
| RU (1) | RU2472525C2 (cs) |
| UA (1) | UA102081C2 (cs) |
| WO (1) | WO2009062454A2 (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ301244B6 (cs) * | 2007-11-14 | 2009-12-16 | Bioveta, A.S. | Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby |
| CZ301548B6 (cs) * | 2008-08-20 | 2010-04-14 | Bittner@Libor | Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití |
| RU2407787C1 (ru) * | 2009-08-13 | 2010-12-27 | Федеральное государственное учреждение науки "Омский научно-исследовательский институт природноочаговых инфекций" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Штамм боррелий генотипа borrelia garinii nt 29, используемый для идентификации боррелий и приготовления диагностических препаратов |
| PL223175B1 (pl) | 2012-10-22 | 2016-10-31 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2102081C1 (ru) * | 1991-07-11 | 1998-01-20 | Иммуно АГ | Иммуногенная композиция против боррелиоза лайма, способ иммунизации млекопитающего против боррелиоза лайма, способ получения белка pc borrelia burgdorferi, диагностический агент для обнаружения b.burgdorferi и способ обнаружения антител к b.burgdorferi |
| US6872550B1 (en) * | 1991-07-11 | 2005-03-29 | Baxter Vaccine Ag | Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens |
| US20070020286A1 (en) * | 1993-11-01 | 2007-01-25 | Dattwyler Raymond J | Recombinant constructs of Borrelia burgdorferi |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0701612T3 (da) * | 1993-04-29 | 1998-09-21 | Immuno Ag | Immunogent præparat af OspC-antigenvacciner til forebyggelse og behandling af Lyme sygdom og rekombinantmetode til fremsti |
| DK0757556T3 (da) * | 1994-04-11 | 2006-10-02 | Wyeth Corp | Borrelia Burgdorferi-bakterin |
| US5846946A (en) * | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| JP5177824B2 (ja) * | 2006-11-03 | 2013-04-10 | シェーリング−プラウ・リミテッド | イヌのライム病のワクチン |
| CZ301244B6 (cs) * | 2007-11-14 | 2009-12-16 | Bioveta, A.S. | Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby |
-
2007
- 2007-11-14 CZ CZ20070791A patent/CZ301244B6/cs unknown
-
2008
- 2008-10-21 WO PCT/CZ2008/000130 patent/WO2009062454A2/en not_active Ceased
- 2008-10-21 EP EP08850812A patent/EP2219670A2/en not_active Ceased
- 2008-10-21 UA UAA201007218A patent/UA102081C2/ru unknown
- 2008-10-21 RU RU2010123897/15A patent/RU2472525C2/ru active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2102081C1 (ru) * | 1991-07-11 | 1998-01-20 | Иммуно АГ | Иммуногенная композиция против боррелиоза лайма, способ иммунизации млекопитающего против боррелиоза лайма, способ получения белка pc borrelia burgdorferi, диагностический агент для обнаружения b.burgdorferi и способ обнаружения антител к b.burgdorferi |
| US6872550B1 (en) * | 1991-07-11 | 2005-03-29 | Baxter Vaccine Ag | Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens |
| US20070020286A1 (en) * | 1993-11-01 | 2007-01-25 | Dattwyler Raymond J | Recombinant constructs of Borrelia burgdorferi |
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2007791A3 (cs) | 2009-05-27 |
| WO2009062454A3 (en) | 2009-07-16 |
| RU2010123897A (ru) | 2011-12-20 |
| WO2009062454A2 (en) | 2009-05-22 |
| UA102081C2 (ru) | 2013-06-10 |
| EP2219670A2 (en) | 2010-08-25 |
| CZ301244B6 (cs) | 2009-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fikrig et al. | Long-term protection of mice from Lyme disease by vaccination with OspA | |
| Barthold et al. | Protective and arthritis-resolving activity in sera of mice infected with Borrelia burgdorferi | |
| Brown et al. | Multicomponent Lyme vaccine: three is not a crowd | |
| JP4301415B2 (ja) | ライム病組み合せ組成物とその使用 | |
| JP6073594B2 (ja) | イヌのライム病のワクチン | |
| Gern et al. | Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii | |
| Gatto et al. | Characterization of, and immune responses of mice to, the purified OmpA-equivalent outer membrane protein of Pasteurella multocida serotype A: 3 (Omp28) | |
| CA2046025A1 (en) | Vaccine against lyme disease and a challenge model for evaluating vaccine efficiency | |
| RU2472525C2 (ru) | Универсальная вакцина для лечения и профилактики болезни лайма для применения у людей и в ветеринарии и способ ее производства | |
| Telford III et al. | Efficacy of human Lyme disease vaccine formulations in a mouse model | |
| UA121097C2 (uk) | Імуногенна композиція, що містить антигени мікоплазм | |
| Šadžiene et al. | A flagella-less mutant of Borrelia burgdorferi as a live attenuated vaccine in the murine model of Lyme disease | |
| US20060251674A1 (en) | Formulations and process for production of Bordetella bronchiseptica P68 antigen and vaccines | |
| Krajacich et al. | Vaccination with the variable tick protein of the relapsing fever spirochete Borrelia hermsii protects mice from infection by tick-bite | |
| Simon et al. | Spirochetes: vaccines, animal models and diagnostics | |
| US9764017B2 (en) | Potomac horse fever isolates | |
| CZ301548B6 (cs) | Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití | |
| CZ18920U1 (cs) | Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a léčbě Uymeské boreliózy pro humánní a veterinární použití | |
| Tuhackova et al. | Testing of the Biocan® B inj. ad us. vet. vaccine and development of the new recombinant vaccine against canine borreliosis | |
| ABD EL-SAMIE | Immunogenicity of experimental Pasteurella multocida vaccine in rabbits | |
| Abhilash | IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A NOVEL INACTIVATED/KILLED PASTEURELLA MULTOCIDA A: 1 VACCINE AGAINST FOWL CHOLERA IN CHICKEN | |
| Hassan | Protective Efficacy of a Borrelia burgdorferi BB0172 Derived-Peptide Based Vaccine Formulation in the Murine Model against Lyme Disease | |
| Rathnamma | Evaluation of bovine mastitis causing Staphylococcus aureus biofilm based vaccine in rabbits | |
| Carroll | Virulence-associated membrane proteins expressed by Borrelia burgdorferi, the causative agent of Lyme disease | |
| Hudson | Characterization of differential expression of vlsE and a conjugal macrolide-lincosamide-streptogramin type B (MLS (B)) resistance determinant from Borrelia burgdorferi |